Comparison of Strategies in Development and Manufacturing of Low Viscosity, Ultra-High Concentration Formulation for IgG1 Antibody

Published:September 14, 2020DOI:


      Monoclonal antibodies requiring higher doses for exerting therapeutic effect but having lower stability, are administered as dilute infusions, or as two (low concentration) injections both resulting in reduced patient compliance. Present research summarizes impact of manufacturing conditions on ultra-high concentration (≥150 mg/mL) IgG1 formulation, which can be administered as one subcutaneous injection. IgG1 was concentrated to ~200 mg/mL using tangential flow filtration (TFF). Alternatively, spray dried (SPD) and spray freeze dried (SFD) IgG1, was reconstituted in 30%v/v propylene glycol to form ultra-high concentration (~200 mg/mL) injectable formulation. Reconstituted, SPD and SFD IgG1 formulations, increased viscosity beyond an acceptable range for subcutaneous injections (<20 cP). Formulations developed by reconstitution of SPD IgG1, demonstrated increase in high and low molecular weight impurities, at accelerated and stressed conditions. Whereas, the stability data suggested reconstituted SFD IgG1 was comparable to control IgG1 formulation concentrated by TFF. Also, formulation of IgG1 diafiltered with proline using TFF, reduce viscosity from ~21.9 cP to ~11 cP at 25 °C and had better stability. Thus, conventional TFF technique stands to be one of the preferred methods for manufacturing of ultra-high concentration IgG1 formulations. Additionally, SFD could be an alternative method for long term storage of IgG1 in a dry powder state.


      To read this article in full you will need to make a payment
      APhA Member Login
      APhA Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Das N.
        Commercializing high-concentration mAbs.
        Biopharm Int. 2016; 29: 47-49
        • Berteau C.
        • Santos O.
        • Wang T.
        • Rojas H.
        • Granger C.
        • Schwarzenbach F.
        Evaluation of the impact of viscosity, injection volume, and injection flow rate on subcutaneous injection tolerance.
        Med Dev Evid Res. 2015; 8: 473-484
      1. Information on approval of new antibody.
        (Available at:)
        Date accessed: April 25, 2020
      2. Information on approval of new antibody.
        (Available at:)
      3. Information regarding antibody concentration and formulation composition for newly approved antibody in European Public Assessment Report (EPAR).
        (Available at:)
        • Yang Y.
        • Velayudhan A.
        • Thornhill N.
        • Farid S.
        Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations.
        Biotechnol Bioeng. 2017; 114: 2043-2056
        • Mathaes R.
        • Koulov A.
        • Joerg S.
        • Mahler H.
        Subcutaneous injection volume of biopharmaceuticals-pushing the boundaries.
        J Pharm Sci. 2016; : 1-5
      4. Information on subcutaneous formulation for trastuzumab, Herceptin SC.
        (Available at:)
        • Whitaker N.
        • Xiong J.
        • Pace S.E.
        • et al.
        A formulation development approach to identify and select stable ultra-high concentration monoclonal antibody formulations with reduced viscosities.
        J Pharm Sci. 2017; 106: 3230-3241
        • Jezek J.
        • Rides M.
        • Derham B.
        • et al.
        Viscosity of concentrated therapeutic protein compositions.
        Adv Drug Deliv Rev. 2011; 63: 1107-1117
        • Yadav S.
        • Shire S.
        • Kalonia D.
        Viscosity behavior of high-concentration monoclonal antibody solutions: correlation with interaction parameter and electroviscous effects.
        J Pharm Sci. 2012; 101: 998-1011
        • Shire S.
        Strategies to deal with challenges of developing high concentration subcutaneous (SC) formulations for monoclonal antibodies (mAbs).
        in: Shire S. Monoclonal Antibodies. first ed. Woodhead Publishing, Cambridge2015: 139-190 (Meeting the Challenges in Manufacturing, Formulation, Delivery and Stability of Final Drug Product)
        • Ginkanga B.
        • Turok R.
        • Hui A.
        • Bowen M.
        • Stauch O.B.
        • Maa Y.
        Manufacturing of high-concentration monoclonal antibody formulations via spray drying-the road to manufacturing scale.
        PDA J Pharm Sci Technol. 2015; 69: 59-73
        • Jena S.
        • Horn J.
        • Suryanarayanan J.
        • Friess W.
        • Aks A.
        Effects of excipient interactions on the state of the freeze-concentrate and protein stability.
        Pharm Res (N Y). 2017; 34: 462-478
      5. New Mixed-Mode Hilic - Advances in Retention Control and Selectivity. SIELC, Inc, 2007 (Newsletter)
        • Bhandare P.
        • Madhavan P.
        • Rao B.M.
        • Rao N.S.
        Determination of amino acid without derivatization by using HPLC - HILIC column.
        J Chem Pharm Res. 2010; 2: 372-380
        • Appelblad P.
        • Tobias J.
        • Pontén E.
        • Wen J.
        Merck SeQuant™ A Practical Guide to HILIC Including ZIC®-HILIC Applications.
        World Wide Web Edition, 2009: 1-33
        • Burnouf T.
        • Sayed M.A.
        • Radosevich M.
        • El-Ekiaby M.
        Comparative removal of solvent and detergent viral inactivating agents from human intravenous immunoglobulin G preparations using SDR Hyper D and C18 sorbents.
        Anal Biochem. 2009; 389: 69-73
        • Felsovalyi F.
        • Janvier S.
        • Jouffray S.
        • Soukiassian H.
        • Mangiagalli P.
        Silicone-oil-based sub visible particles: their detection, interactions, and regulation in prefilled container closure systems for biopharmaceuticals.
        J Pharm Sci. 2012; 101: 4569-4583
      6. Maa Y, Nguyen P. Method of spray freeze drying proteins for pharmaceutical administration. US Patent 2001;US 6,284,282 B1.

        • Sonner C.
        • Maa Y.
        • Lee G.
        Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability.
        J Pharm Sci. 2002; 91: 2122-2139
        • Malarkani K.
        • Sarkar I.
        • Selvam S.
        Denaturation studies on bovine serum albumin–bile salt system: bile salt stabilizes bovine serum albumin through hydrophobicity.
        J Pharm Anal. 2018; : 27-36
        • Albani S.
        • Ribeiro da Silva M.
        • Takagi M.
        • Cabrera-Crespo J.
        Improvement in the purification process of the capsular polysaccharide from Haemophilus influenzae type b by using tangential ultrafiltration and diafiltration.
        Appl Biochem Biotechnol. 2012; 167: 2068-2075
      7. Kybella® [package Insert]. Allergan USA, Inc, Irvine, CA, USA2018
      8. Belkyra®, [package Insert]. Allergan Pharmaceuticals International Ltd., Dublin 17, Ireland2019
      9. Fungizone®, [package Insert]. Princeton, NJ, USA2009
      10. Flulaval®, [package Insert]. GlaxoSmithKline Inc., Mississauga, Ontario, Canada2020
      11. Fluarix®, [package Insert]. GlaxoSmithKline Inc., Munich, Germany2020
      12. Bexsero®, [package insert]. Sovicille (SI), Italy: GSK Vaccines, Srl; 201529.

        • Miao F.
        • Velayudhan A.
        • DiBella E.
        • et al.
        Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
        Biotechnol Prog. 2009; 25: 964-972
        • Miranda-Hernández M.
        • López-Morales C.
        • Lara N.
        • et al.
        Pharmacokinetic comparability of a biosimilar trastuzumab anticipated from its physicochemical and biological characterization.
        BioMed Res Int. 2015; 2015: 874916
        • Stoner R.
        • Fischer N.
        • Nixon L.
        • et al.
        Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations.
        J Pharm Sci. 2004; 93: 2332-2342
        • Teerters M.
        • Bezila D.
        • Benner T.
        • Alfonso P.
        • Alred P.
        Predicting diafiltration solution compositions for final Ultra filtration and diafiltration steps for monoclonal antibodies.
        Biotechnol Bioeng. 2011; 108: 1338
        • Roberts D.
        • Keeling R.
        • Tracka C.F.
        • et al.
        Specific ion buffer effect on protein-protein interactions of monoclonal antibody.
        Mol Pharm. 2014; 12: 179-193
        • Dias C.
        • Abosaleem B.
        • Crispino C.
        • Gao B.
        • Shaywitz A.
        Tolerability of high-volume subcutaneous injections of a viscous placebo buffer: a randomized, crossover study in healthy subjects.
        AAPS PharmSciTech. 2015; 16: 1101-1107
        • Siew A.
        Delivering high-concentration protein formulations.
        Pharm.Tech. 2018; 42: 30-33
        • Prasetyono T.
        • Adhistana P.
        Laboratory study on injection force measurement on syringe and needle combinations.
        Malays J Med Sci. 2019; 26: 66-76
      13. In formation on specifications for Glide force and break loose force for prefilled syringes: ISO 11040-8:2016 (en) Prefilled syringes — Part 8: requirements and test methods for finished prefilled syringes.
        (Available at:)
        Date accessed: March 1, 2020
        • Faghihi H.
        • Najafabadi A.
        • Vatanara A.
        Optimization and characterization of spray-dried IgG formulations: a design of experiment approach.
        Daru. 2017; 25: 22 1-9
        • Yowa H.
        • Routh A.
        Colloidal buckets formed via internal phase separation.
        Soft Matter. 2008; 4: 2080-2085
        • Wang W.
        Advanced protein formulations.
        Protein Sci. 2015; 24: 1031-1039
        • Yang M.
        • Shenoy B.
        • Disttler M.
        • et al.
        Crystalline monoclonal antibodies for subcutaneous delivery.
        Proc Natl Acad Sci U S A. 2003; 100: 6934-6939
        • Srinivasan C.
        • Weight A.K.
        • Bussemer T.
        • Klibanov A.M.
        Non-aqueous suspensions of antibodies are much less viscous than equally concentrated aqueous solutions.
        Pharm Res (N Y). 2013; 30: 1749-1757
        • Anderson F.
        Final report on the safety assessment of propylene glycol and polypropylene glycols.
        J Am Coll Toxicol. 1994; 13: 437-491
      14. Select committee on GRAS substances (SCOGS) opinion: propylene glycol and propylene glycol monostearate report number: 27 (1973).
        (Available from:)
        • European Medicines Agency (EMA) report (EMA/CHMP/334655/2013)
        Questions and answers on Propylene glycol used as an excipient in medicinal products for human use.
        (Available from:)
        • Pabari R.
        • Ryan B.
        • McCarthy C.
        • Ramtoola Z.
        Effect of microencapsulation shear stress on the structural integrity and biological activity of a model monoclonal antibody.
        Trastuzumab Pharm. 2011; 3: 510-524
        • Lee J.
        • Kang H.
        • Bae J.
        • et al.
        Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
        mAbs. 2018; 10: 547-571
        • Schüle S.
        • Wolfgang F.
        • Bechtold-Peters K.
        • Garidel P.
        Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations.
        Eur J Pharm Biopharm. 2007; 65: 1-9
        • Ng K.
        • Zhao L.
        • Meyer J.
        • Rittmann-Grauer L.
        • Manning M.
        Use of circular dichroism spectroscopy in determining the conformation of a monoclonal antibody prior to its incorporation in an immunoliposome.
        J Pharm Biomed Anal. 1997; 16: 507-513